Traws Pharma (NASDAQ:TRAW) Posts Earnings Results, Beats Expectations By $0.18 EPS

Traws Pharma (NASDAQ:TRAW) announced its earnings results on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.18, FiscalAI reports.

Traws Pharma Stock Performance

Shares of TRAW stock traded down $0.03 on Friday, hitting $0.57. 76,075 shares of the company’s stock traded hands, compared to its average volume of 110,422. Traws Pharma has a one year low of $0.43 and a one year high of $3.27. The company’s fifty day simple moving average is $0.73 and its 200 day simple moving average is $1.37. The stock has a market capitalization of $8.65 million, a price-to-earnings ratio of -0.34 and a beta of 1.57.

Institutional Trading of Traws Pharma

Hedge funds have recently added to or reduced their stakes in the business. Squadron Capital Management LLC purchased a new stake in Traws Pharma during the fourth quarter valued at about $806,000. Ikarian Capital LLC increased its holdings in shares of Traws Pharma by 2,280.0% in the fourth quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after buying an additional 649,649 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of Traws Pharma by 121.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after acquiring an additional 400,000 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Traws Pharma in the 4th quarter valued at about $220,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Traws Pharma during the 4th quarter valued at about $175,000. 7.95% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TRAW shares. Citigroup downgraded Traws Pharma to a “neutral” rating in a research report on Monday, June 15th. Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. LADENBURG THALM/SH SH cut Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. Finally, HC Wainwright restated a “negative” rating and issued a $1.00 target price on shares of Traws Pharma in a research report on Thursday, June 18th. Three investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Traws Pharma presently has an average rating of “Reduce” and a consensus target price of $1.00.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.